ストックスクリーナーアプリを入手
4.38
0.45%
-0.02
プレマーケット:
4.42
0.04
+0.91%
前日終値:
$4.40
開ける：
$4.4
24時間の取引高:
1.33M
Relative Volume:
0.35
時価総額：
$453.73M
収益：
-
当期純損益:
$-132.00M
株価収益率:
-2.2723
EPS:
-1.9276
ネットキャッシュフロー:
$-96.76M
1週間 パフォーマンス:
-21.93%
1か月 パフォーマンス:
+44.55%
6か月 パフォーマンス:
+7.35%
1年 パフォーマンス:
+71.76%
1日の値動き範囲:
$4.2964
$4.50
1週間の範囲:
$4.2964
$5.74
52週間の値動き範囲:
$1.61
$6.42
Larimar Therapeutics Inc Stock (LRMR) Company Profile
名前
Larimar Therapeutics Inc
セクター
電話
844-511-9056
住所
THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD, PA
Compare LRMR vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LRMR
Larimar Therapeutics Inc
|
4.38 | 455.80M | 0 | -132.00M | -96.76M | -1.9276 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.49 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.05 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
706.03 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.42 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
287.33 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Larimar Therapeutics Inc Stock (LRMR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-29 | 開始されました | Truist | Buy |
| 2024-10-16 | 開始されました | Oppenheimer | Outperform |
| 2024-10-03 | 開始されました | Wedbush | Outperform |
| 2024-10-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-04 | 開始されました | Robert W. Baird | Outperform |
| 2024-04-03 | 開始されました | Leerink Partners | Outperform |
| 2023-11-17 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-19 | 開始されました | Guggenheim | Buy |
| 2022-02-15 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-02-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-02-01 | 開始されました | William Blair | Outperform |
すべてを表示
Larimar Therapeutics Inc (LRMR) 最新ニュース
Larimar surges on FDA breakthrough status for lead asset - MSN
IPO Launch: Does Larimar Therapeutics Inc have consistent dividend growth2026 Summary & Risk Managed Trade Strategies - baoquankhu1.vn
Should I invest in Larimar Therapeutics Inc before earningsSwing Trade & Growth Focused Investment Plans - baoquankhu1.vn
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Sees Significant Decrease in Short Interest - MarketBeat
Aug Gainers: How volatile is Larimar Therapeutics Inc stockTrade Exit Summary & AI Based Trade Execution Alerts - baoquankhu1.vn
FDA grants breakthrough status to Larimar’s nomlabofusp - MSN
Mangrove Partners IM LLC Sells 327,997 Shares of Larimar Therapeutics, Inc. $LRMR - MarketBeat
Investors Purchase Large Volume of Larimar Therapeutics Call Options (NASDAQ:LRMR) - MarketBeat
Larimar Therapeutics (NASDAQ:LRMR) Stock Price Down 8%Should You Sell? - MarketBeat
Larimar Advances Nomlabofusp Toward 2026 BLA Submission - The Globe and Mail
LRMR: Nomlabofusp shows strong efficacy and regulatory momentum for Friedreich's ataxia, with BLA submission planned for 2026 - TradingView
Larimar Therapeutics posts updated corporate deck outlining nomlabofusp BLA plan, Q2 2026 topline and cash runway - TradingView
Larimar Therapeutics (LRMR) advances nomlabofusp toward 2026 BLA and Phase 3 - Stock Titan
Larimar Therapeutics, Inc. (NASDAQ:LRMR) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Blue Owl Capital Holdings LP Has $18.91 Million Stock Holdings in Larimar Therapeutics, Inc. $LRMR - MarketBeat
ETF Watch: Is Larimar Therapeutics Inc. stock a good choice for value investorsMarket Movers & Verified Swing Trading Watchlists - Naître et grandir
LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month? - TradingView
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March - Sahm
Larimar Therapeutics Launches $75 Million Public Offering of Common Stock and Pre-Funded Warrants - Global Legal Chronicle
Larimar Therapeutics price target raised to $12 from $11 at Wedbush - finance.yahoo.com
FDA Grants Breakthrough Status to Larimar’s Nomlabofusp - MyChesCo
Wedbush Maintains Outperform on Larimar Therapeutics, Inc. (LRMR) March 2026 - Meyka
LRMR Stock Rating Maintained Outperform by Wedbush, Price Target - GuruFocus
Wedbush raises Larimar Therapeutics stock price target to $12 By Investing.com - Investing.com Canada
Wedbush raises Larimar Therapeutics stock price target to $12 - Investing.com
Larimar Therapeutics (NASDAQ:LRMR) Price Target Raised to $12.00 - MarketBeat
Larimar Therapeutics Stock (LRMR) Opinions on Public Offering and Insider Purchases - Quiver Quantitative
LRMR News & Events - Intellectia AI
Larimar Therapeutics: Deerfield entities buy $25m in stock By Investing.com - Investing.com South Africa
Larimar Therapeutics: Deerfield entities buy $25m in stock - Investing.com Nigeria
James Flynn Acquires 5,000,000 Shares of Larimar Therapeutics (NASDAQ:LRMR) Stock - MarketBeat
Insider Buying: Frank Thomas Acquires Additional Shares of Larim - GuruFocus
Wedbush Adjusts Larimar Therapeutics PT to $12 From $11, Maintains Outperform Rating - marketscreener.com
Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? - Yahoo Finance
Larimar Therapeutics Announces Upsized Public Equity Offering - TipRanks
Larimar Therapeutics Prices $5.00 Public Offering, Nets ~$107.6 Million as Option Is Exercised - TradingView
Larimar Therapeutics prices $100M stock offering at $5 per share - Investing.com Australia
Larimar Therapeutics Prices Upsized $100 Million Public Stock Offering - marketscreener.com
Larimar Therapeutics stock falls 8% on upsized $100 million offering By Investing.com - Investing.com Canada
What is Lifesci Capital's Estimate for LRMR FY2025 Earnings? - MarketBeat
Larimar Therapeutics Prices Upsized 20 Mln Public Offering At $5.00 Per Share, Stock Down - Nasdaq
Larimar Therapeutics (LRMR) Upsizes Public Offering to Raise $10 - GuruFocus
Larimar Therapeutics announces pricing of upsized $100 million underwritten public offering - marketscreener.com
Larimar Prices $100M Stock Sale After Record Rally Fueled By FDA Breakthrough Tag For Protein Replacement Therapy - Asianet Newsable
LRMR Expands Offering to $100 Million - GuruFocus
Larimar Therapeutics Prices Upsized Public Offering - Intellectia AI
Larimar Therapeutics, Inc. Prices Upsized Public Offering of 20 Million Shares at $5.00 Each - Quiver Quantitative
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering - Stock Titan
Larimar Therapeutics launches $75M public stock offering By Investing.com - Investing.com Australia
Larimar Therapeutics Inc (LRMR) 財務データ
収益
当期純利益
現金流量
EPS
Larimar Therapeutics Inc (LRMR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hamilton Thomas Edward | Director |
Feb 27 '26 |
Buy |
5.00 |
100,000 |
500,000 |
664,798 |
| THOMAS FRANK E | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
7,000 |
| SHERMAN JEFFREY W | Director |
Feb 27 '26 |
Buy |
5.00 |
5,000 |
25,000 |
5,000 |
| Flynn James E | Director |
Jul 31 '25 |
Buy |
3.20 |
9,375,000 |
30,000,000 |
9,538,945 |
0.02%
0.46%
大文字化:
|
ボリューム (24 時間):